Protein– tag –
-
Xcellon Biologics Acquires NextCure GMP Facility, Establishes End-to-End CRDMO for Next-Gen Bioconjugates, Streamlining Development from Discovery to Clinical Supply
Outsourced Pharma USA Overview Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, transforming into an end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) for next-generation bioconju... -
Korro Bio Accelerates RNA Editing Platform into Clinic with First-in-Human Trial for Hyperammonemia and Designation of AATD Candidate
GlobeNewswire (via Korro Bio, Inc.) USA Overview Korro Bio has announced plans to initiate first-in-human clinical trials for its hyperammonemia treatment candidate, KRRO-121, in late 2026. Concurrently, the company designated KRRO-111 a... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
Monte Rosa’s AI-Powered Molecular Glue Degrader MRT-6160 Achieves >90% VAV1 Degradation and Potent Cytokine Suppression in Phase 1, Prompting Multiple Novartis-Led Phase 2 Trials
Quartr Sweden Overview Monte Rosa Therapeutics has announced that its AI-driven QuEEN platform's molecular glue degrader (MGD) MRT-6160 achieved over 90% VAV1 protein degradation and potent cytokine suppression in Phase 1 trials. This su... -
Biopharma’s Bottleneck: Critical CDMO Capacity Shortage Hampers Advanced Therapy Development
Contract Pharma USA Overview A severe capacity crunch within Contract Development and Manufacturing Organizations (CDMOs) is impeding the biopharmaceutical industry. Recent data reveals nearly half of biopharma firms struggle to secure C... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
AsymBio Secures $184M to Scale Biologics CDMO Capacity for Advanced Therapies like ADCs and Bispecific Antibodies
Megaproject China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (1.24 billion RMB) from investors including Asymchem Group and Hillhouse Qirui. This substantial investment will drive th... -
Merck Ups 2026 Guidance on Strong Q2, KEYTRUDA Bladder Cancer Expansion, and ENFLONSIA RSV Indication Broadening Bolstering Investment Story
Simply Wall St USA Overview Merck achieved robust Q2 2026 performance and subsequently upgraded its full-year guidance, driven by key regulatory advancements. The company's investment narrative is significantly strengthened by the new bl... -
C4 Therapeutics Grants Stock Options to New Employees Under Nasdaq Rule, Bolstering TPD Talent Acquisition
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) announced it has granted stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4). This inducement grant is a critical component of the company's strategy to adv...
